Novel treatment option for KRAS wild-type pancreatic cancer

Gemcitabine plus nimotuzumab demonstrated overall survival (OS) benefits over gemcitabine alone for patients with KRAS wild-type metastatic pancreatic ductal adenocarcinoma (mPDAC) or locally advanced pancreatic cancer (LAPC). The results of the phase 3 Notable trial show the value of determining KRAS status in pancreatic cancer.

Activation of the epidermal growth factor receptor (EGFR)-Ras-Raf-MEK-ERK pathway plays a part in patients with KRAS wild-type pancreatic cancer [1]. Therefore, the phase 3 Notable trial (NCT02395016) randomised patients with KRAS wild-type locally advanced or metastatic pancreatic cancer to gemcitabine and placebo (n=41) or gemcitabine plus nimotuzumab (n=41), which is an EGFR-targeting monoclonal antibody [2,3]. OS was the primary endpoint of this study. Prof. Thomas Seufferlein (Ulm University Hospital, Germany) presented the results [2].

The combination therapy arm outperformed the placebo arm significantly for OS (10.9 months vs 8.5 months; HR 0.50; P=0.024), decreasing the risk of mortality by 50%. In addition, the 1-year and 3-year OS rates were 43.6% and 13.9% for patients treated with nimotuzumab, and 26.8% and 2.7% for patients who received placebo.

Importantly, the combination therapy was well tolerated and no substantial increase in grade 3 adverse events (AEs) was observed among patients who received nimotuzumab. The most frequently reported AEs in the nimotuzumab arm were neutropaenia (11.1%), leukopaenia (8.9%), and thrombocytopaenia (6.7%).

Prof. Seufferlein added that the OS curves of the 2 treatment arms separated rather late, suggesting there might be subgroups within the KRAS wild-type subgroup of tumours that behave differently in response to nimotuzumab.

“This trial demonstrated that it is worth determining KRAS status in pancreatic cancer. Gemcitabine plus nimotuzumab displayed itself as a novel option for patients with KRAS wild-type mPDAC/LAPC who otherwise would have received only gemcitabine. Finally, it would be interesting to see how nimotuzumab plus chemotherapy would behave in the KRAS wild-type mPDAC population,” said Prof. Seufferlein.

1. Luchini C, et al. J Exp Clin Cancer Res. 2020;39(1):227.


2. Seufferlein T, et al. Is it worth determining KRAS Status in Pancreas Cancer? LBA 4011, ASCO 2022 Annual Meeting, 3–7 June, Chicago, IL, USA.


3. Qin S, et al. Nimotuzumab combined with gemcitabine versus gemcitabine in KRAS wild‐type locally advanced or metastatic pancreatic cancer: a prospective, randomized‐controlled, double‐blinded, multicenter, and phase III clinical trial. J Clin Oncol. LBA4011, ASCO 2022 Annual Meeting, 3–7 June, Chicago, IL, USA.

Copyright ©2022 Medicom Medical Publishers





Posted on 7 June, 2022